Abstract | BACKGROUND/AIMS: METHODS: RESULTS: The overall opinion of the physicians and the patients was in favour of lodoxamide at day 10 of the study. At this time, 86% of lodoxamide treated and 49% of NAAGA treated patients considered they had improved. The patients' opinion favoured lodoxamide at day 28 and both physicians' and patients' evaluations were in favour of lodoxamide at day 42. Evaluation of signs and symptoms indicated superiority of lodoxamide at days 42 and 56. Both treatments were well tolerated. CONCLUSION:
|
Authors | D Denis, E Bloch-Michel, P Verin, A Sebastiani, M Tazartes, L Helleboid, A Di Giovanni, M Lecorvec |
Journal | The British journal of ophthalmology
(Br J Ophthalmol)
Vol. 82
Issue 10
Pg. 1135-8
(Oct 1998)
ISSN: 0007-1161 [Print] England |
PMID | 9924299
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Allergic Agents
- Dipeptides
- isospaglumic acid
- Oxamic Acid
- lodoxamide ethyl
|
Topics |
- Adolescent
- Adult
- Aged
- Anti-Allergic Agents
(adverse effects, therapeutic use)
- Child
- Child, Preschool
- Chronic Disease
- Conjunctivitis, Allergic
(drug therapy)
- Dipeptides
(adverse effects, therapeutic use)
- Double-Blind Method
- Female
- Humans
- Male
- Middle Aged
- Oxamic Acid
(adverse effects, analogs & derivatives, therapeutic use)
- Patient Satisfaction
- Treatment Outcome
|